Alectinib is under clinical development by Chugai Pharmaceutical and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Alectinib’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Alectinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Alectinib overview
Alectinib (Alecensa/Alecensaro) is an antineoplastic agent. It is an anaplastic lymphoma kinase (ALK) inhibitor. It is formulated as hard gelatin capsules for oral route of administration. Alecensa is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib and as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small cell lung cancer (NSCLC). Alecensa is also indicated for recurrent or refractory ALK fusion gene-positive anaplastic large-cell lymphoma.
Alectinib is under development for the treatment of central nervous system (CNS) tumor, advanced or metastatic solid tumors, non-small cell lung cancer (NSCLC) as an adjuvant therapy and first line therapy. It is administered through oral route as a capsule.
Chugai Pharmaceutical overview
Chugai Pharmaceutical (Chugai), a subsidiary of Hoffmann-La Roche Ltd, is focused on the research, development, manufacturing, commercialization, import and export of biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of various therapeutic areas including, cancer; bone and joint diseases; renal diseases; immune disorders and infectious diseases and others. It also offers drugs to aid the kidney, liver and other organ transplants. It also has a range of product candidates in its pipeline. Operating through its network of subsidiaries, the company offers its pharmaceutical products in overseas markets including North America, Europe and Asia. Chugai is headquartered in Tokyo, Japan.
Quick View Alectinib LOA Data
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Developers |
|
Highest Development Stage |
|